Harvard's AI model predicts immunotherapy outcomes across cancer types with improved accuracy
Harvard researchers developed COMPASS, a generalizable AI that predicts which cancer patients will respond to immune checkpoint inhibitors. The AI model outperformed existing approaches by 8.5% and provides interpretable results based on tumor gene activity. Published in Nature Medicine, this advance could transform personalized medicine and clinical trial enrollment.